Glycemic control and the heart: it matters how you get there

Bloomgarden, Zachary T.

doi:10.1111/1753-0407.12398

Cited by 3 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TZDs should be discontinued in severe hospitalized cases due to safety concerns about fluid retention and heart failure deterioration [ 29 ]. On the other hand, the significant insulin-sensitizing and anti-inflammatory effects of these agents [ 130 , 131 ], as well as their potential to ameliorate hepatic steatosis and inflammation [ 132 ], should not be disregarded.…”

Section: General Recommendations For the Management Of Hyperglycemmentioning

confidence: 99%

Clinical Management of Diabetes Mellitus in the Era of COVID-19: Practical Issues, Peculiarities and Concerns

Koliaki

Tentolouris

Eleftheriadou

et al. 2020

JCM

View full text Add to dashboard Cite

The management of patients with diabetes mellitus (DM) in the era of the COVID-19 pandemic can be challenging. Even if they are not infected, they are at risk of dysregulated glycemic control due to the restrictive measures which compromise and disrupt healthcare delivery. In the case of infection, people with DM have an increased risk of developing severe complications. The major principles of optimal care for mild outpatient cases include a patient-tailored therapeutic approach, regular glucose monitoring and adherence to medical recommendations regarding lifestyle measures and drug treatment. For critically ill hospitalized patients, tight monitoring of glucose, fluids, electrolytes, pH and blood ketones is of paramount importance to optimize outcomes. All patients with DM do not have an equally increased risk for severity and mortality due to COVID-19. Certain clinical and biological characteristics determine high-risk phenotypes within the DM population and such prognostic markers need to be characterized in future studies. Further research is needed to examine which subgroups of DM patients are expected to benefit the most from specific antiviral, immunomodulatory and other treatment strategies in the context of patient-tailored precision medicine, which emerges as an urgent priority in the era of COVID-19.

show abstract

Section: General Recommendations For the Management Of Hyperglycemmentioning

confidence: 99%

Clinical Management of Diabetes Mellitus in the Era of COVID-19: Practical Issues, Peculiarities and Concerns

Koliaki

Tentolouris

Eleftheriadou

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Trials that have included extended observation over decades of diabetic people without baseline CV disease (CVD) have certainly suggested such benefit in prediabetes, type 2 diabetes (T2D), and type 1 diabetes . However, studies enrolling people with diabetes with high CV risk or with underlying CVD at baseline and performed over 2–5 year periods have, in general, failed to demonstrate CV benefit of glycemic interventions, although recent studies have suggested that certain glucose‐lowering agents may be associated with non‐glycemic CV benefits . The need for safe and useful therapeutic approaches cannot be overstated, recognizing the implication of the longer studies that treatments must be given over decades prior to the development of CV complications.…”

mentioning

confidence: 99%

“…7 However, studies enrolling people with diabetes with high CV risk or with underlying CVD at baseline and performed over 2-5 year periods have, in general, failed to demonstrate CV benefit of glycemic interventions, 8 although recent studies have suggested that certain glucose-lowering agents may be associated with non-glycemic CV benefits. 9 The need for safe and useful therapeutic approaches cannot be overstated, recognizing the implication of the longer studies that treatments must be given over decades prior to the development of CV complications. With the growth in use of dipeptidyl peptidase-4 inhibitors (DPP-4i), 10 it is important to consider how these agents fit in our therapeutic armamentarium.…”

mentioning

confidence: 99%